Sort
82,697 grants matching “vaccine development”
T CELL MEMORY TO PATHOGENS: GENERATION AND FUNCTION
$1,618,318Trudeau Institute, Inc. · P01 · FY2003 · AI
Medical Scientist Training Program
$1,618,270Christopher S. Williams · Vanderbilt University · T32 · FY2024 · GM
Combining germline-targeting, B cell immunofocusing and Env-Ab co-evolution strategies to induce HIV Envelope V2-apex broadly neutralizing antibodies
$1,618,119Raiees Ahmad Andrabi · Scripps Research Institute, The · R61 · FY2022 · AI
UCLA AIDS Prevention and Treatment Clinical Trials Unit
$1,617,872Judith S. Currier · University Of California Los Angeles · U01 · FY2007 · AI
Toxic substances in the environment
$1,617,750Martyn T Smith · University Of California Berkeley · P42 · FY2024 · ES
NEW LIVE VIRAL VECTORS AS CANDIDATE AIDS VACCINES
$1,616,957Emory University · P01 · FY2002 · AI
Modeling affinity maturation at molecular resolution
$1,616,696Thomas B Kepler · Boston University Medical Campus · U19 · FY2015 · AI
Production of an NP-ISS conjugate vaccine to combat pandemic influenza.
$1,616,687Gary A Van Nest · Dynavax Technologies Corporation · U01 · FY2008 · AI
Functional and dysfunctional human CD4 T cell and B cell responses to bacteria and viruses
$1,616,471Shane P Crotty · La Jolla Institute For Immunology · U19 · FY2022 · AI
University of Washington Arboviral Research Network (UWARN)
$1,616,309Wesley C Van Voorhis · University Of Washington · U01 · FY2024 · AI
Simian Vaccine Evaluation Unit: Operation of a Nonhuman Primate Breeding Colony
$1,616,284Francois Villinger · University Of Louisiana At Lafayette · N01 · FY2020 · AI
Manipulating Epitope Immunodominance and Tracking B-cell-Antigen Interactions for Vaccine Design.
$1,616,010Amelia Escolano · Wistar Institute · DP2 · FY2022 · AI
BIGDATA: IA: A multi-level approach for global optimization of the surveillance and control of infectious disease in the swine industry
$1,616,000Beatriz Martinez Lopez · University Of California-Davis · · FY2019 · CSE
Cold Chain-Independent, Needle-Free Mucosal Virosomal Vaccine to Prevent HIV-1 Acquisition at Mucosal Levels
$1,615,853Ruth Margrit Ruprecht · University Of Louisiana At Lafayette · U19 · FY2022 · AI
Coordinating Research on Emerging Arboviral Threats Encoing the Neotropics (CREATE-NEO)
$1,615,615Nikos Vasilakis · University Of Texas Med Br Galveston · U01 · FY2020 · AI
Vanderbilt HIV Clinical Trials Unit
$1,615,311David W Haas · Vanderbilt University Medical Center · UM1 · FY2018 · AI
CTL and HIV Polymorphisms in Heterosexual Transmission
$1,615,187Eric Hunter · Emory University · R01 · FY2019 · AI
Innovative Influenza Therapeutic and Prophylactic for Biodefense Applications
$1,615,004Jane Ryan · Biota Scientific Management · U01 · FY2009 · AI
Pathogenesis and Vaccine Studies Of Simian Immunodeficiency Virus Infection Of Monkeys
$1,614,805Vanessa M. Hirsch · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI
SOFT TISSUE SARCOMA PROGRAM PROJECT
$1,614,414Sloan-Kettering Institute For Cancer Res · P01 · FY2000 · CA
Mosquito Immune Responses and Malaria Transmission
$1,614,127Carolina Barillas-Mury · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI
IL-2IL-15 Cytokine Receptor: Implications for Cancer Therapy and Vaccine Design
$1,614,069Thomas Waldmann · Division Of Clinical Sciences - Nci · ZIA · FY2010 · CA
Antibody effector function in protection against HIV-1
$1,613,613Dennis R. Burton · Scripps Research Institute, The · R37 · FY2010 · AI
Immunotherapy with High Frequency, CEA Specific T Cells
$1,613,175Duke University · P01 · FY2004 · CA
Human Papillomavirus (HPV) Natural History, Genomics and Risk Assessment
$1,612,518Mark Schiffman · Division Of Cancer Epidemiology And Genetics · ZIA · FY2018 · CA